A year-and-a-half after graduating from college in 1999, the last thing that Steve Smith, now 25, expected was for his kidneys to fail. Although the Nashville resident had always been active and healthy and had no family history of kidney disease, shortly after moving to Los Angeles, he began experiencing what he describes as "strange symptoms" that he thought might be associated with mononucleosis. When he went to the doctor, he learned that his kidneys had failed.
He moved back to Nashville and received his first kidney transplant in May, 2000, but his body developed high antibodies and rejected the organ seven months later. Worse still, because of the high antibodies, it was unlikely that doctors would be able to find another match for him as his body would very likely see another donor kidney as a foreign intruder and reject it.
However, neither Smith nor his physicians were willing to give up. His doctors had heard of an innovative kidney transplant therapy that was developed at Cedars-Sinai Medical Center in Los Angeles. They told Smith about it, and he went online to do additional research. He learned that the therapy, known as intravenous immunoglobulin (IVIG) makes kidney transplantation possible between donors and recipients who previously would have been considered poor matches. Smith learned that a new test could help determine which patients were most likely to benefit.
IVIG therapy, which has been used for several years for other diseases, was adapted for use in the field of transplantation by researchers led by Stanley C. Jordan, M.D., medical director of Cedars-Sinais Kidney Transplant Program, director of Pediatric Nephrology and Transplant Immunology, and professor of pediatrics at the University of California, Los Angeles. In September, 2002, Smith traveled to Los Angeles where he was seen by Dr. Jordan.
After successfully undergoing the new test to determine whether the IVIG therapy would prove effective for Smith, his donor-friend also flew to Los Angeles for additional testing. The results showed that the therapy would likely be effective in Smiths case, so the transplant was scheduled for a couple of weeks later.
Prior to the transplant, Smith received two, four-hour treatments of IVIG therapy - an intravenous drip while he was on dialysis. About a month after his transplant, he received a final treatment with IVIG.
"I feel good!" he says now. "The blood test scores are great. I just took my donor on a cruise and Im trying to get my life back on track."
Just a few years ago, Smith would have been facing a lifetime of kidney dialysis and little hope for a transplant. Thanks to these new medical advances, though, he has moved back to Los Angeles to resume his career in the entertainment industry.
Coming at a time when the waiting list for cadaveric kidneys is predicted to climb to 100,000 patients by 2006 and 150,000 by 2010, these new techniques may result in greater access to transplantation for many patients who otherwise would have had little hope. In fact, a study published by Dr. Jordan in the American Journal of Transplantation in 2002, showed that the procedure appears to dramatically increase success for patients receiving cadaver organs as well as those receiving kidneys from living relatives or friends.
The infusion of IVIG has been used for several years to help prevent rejection, even in difficult cases when other anti-rejection methods have failed. While most anti-rejection medications suppress the immune system entirely, thereby increasing the patients risk of infection, IVIG appears to control immune responses that would harm a transplanted organ, while boosting protection from infection.
Dr. Jordan and his team have now fine-tuned their techniques in the laboratory to predict which patients would most likely benefit from IVIG. By introducing IVIG into the analysis, they are able to make poor matches much more compatible.
The process of "crossmatching" is performed by combining a sample of the potential recipients blood serum with a sample of the potential donors white cells. The question of compatibility revolves around human leukocyte antigen (HLA), proteins that regulate the way the body recognizes foreign substances.
If the recipient has developed antibodies to the donors HLA, the antibody attacks the antigen as an invader. This is called a "positive" crossmatch and it indicates that the recipients immune system would reject the donors organ. The potential recipient is said to be "sensitized" to the donors HLA. If the recipient does not have antibodies against the donors HLA - a negative crossmatch - this reaction does not occur.
Because highly sensitized patients have comparatively high risks of rejection and low organ-survival success rates, transplants for these patients have decreased drastically in the past 15 years. Further, there have been no therapies available to resolve issues of immune incompatibility, leaving most patients to rely on dialysis for extended periods of time in the hope that a well-matched kidney might become available.
But Dr. Jordan and his colleagues showed that adding IVIG during the crossmatch process in the laboratory inhibited the destruction of incompatible HLA-bearing cells, in most cases, essentially changing a positive crossmatch to a negative one. Subsequently, patients were able to receive IVIG therapy and undergo a transplant, if the crossmatch became negative after IVIG treatment.
"Based on our results, the IVIG crossmatch technique is a very effective predictor of the way IVIG will help a patients immune system to accept a transplanted organ," said Dr. Jordan. "Those who have a good response in the laboratory can be given IVIG, which eliminates the positive crossmatch and allows for successful transplantation, in most cases. Therefore, a positive crossmatch does not necessarily mean that a patient cannot receive a transplant."
Cedars-Sinai Medical Center is one of the largest nonprofit academic medical centers in the Western United States. For the fifth straight two-year period, it has been named Southern Californias gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. Named one of the 100 "Most Wired" hospitals in health care in 2001, the Medical Center ranks among the top 10 non-university hospitals in the nation for its research activities.
Sandy Van | Van Communications
Investigators may unlock mystery of how staph cells dodge the body's immune system
22.09.2017 | Cedars-Sinai Medical Center
Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital
Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.
A warming planet
Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.
The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...
Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
22.09.2017 | Life Sciences
22.09.2017 | Medical Engineering
22.09.2017 | Physics and Astronomy